CPG:LSECompass Group PLC Analysis
Data as of 2026-03-10 - not real-time
£2,283.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Compass Group trades at £2,283, comfortably above its 200‑day SMA of £2,447, indicating a longer‑term bearish bias despite a current price above the 20‑day (£2,184) and 50‑day (£2,231) averages. The RSI sits at 58, suggesting neutral momentum, while the MACD histogram remains strongly positive, giving a short‑term bullish signal. Volatility is elevated at over 30% for the past 30 days, but the beta of 0.17 points to low market‑wide sensitivity. A DCF‑derived fair value of £1,720 places the stock well above intrinsic estimates, and the PE of 27.8× further signals a premium valuation. The company posted 7% organic revenue growth in Q1 FY26 with 96% client retention, yet shares slipped 3% on concerns over a slowdown and AI‑related disruption. Analysts’ median target of £2,982 implies roughly 24% upside, though the high debt‑to‑equity ratio of 90.7% and a P/B of 673 raise valuation caution.
The dividend yield of 2.12% and a payout ratio near 56% provide modest income, but leverage and a max drawdown of 24% suggest risk. The “Extreme Greed” sentiment on the Fear & Greed Index reflects strong market appetite, potentially inflating price. Overall, the stock presents a mixed picture: short‑term technical optimism against a backdrop of overvaluation and sector volatility. Investors should weigh the solid cash‑flow generation and client base against the elevated leverage and valuation gaps. The consensus recommendation remains a “buy,” but execution timing is critical. Maintaining a disciplined approach to entry levels near support (£2,000) could improve risk‑adjusted returns.
The dividend yield of 2.12% and a payout ratio near 56% provide modest income, but leverage and a max drawdown of 24% suggest risk. The “Extreme Greed” sentiment on the Fear & Greed Index reflects strong market appetite, potentially inflating price. Overall, the stock presents a mixed picture: short‑term technical optimism against a backdrop of overvaluation and sector volatility. Investors should weigh the solid cash‑flow generation and client base against the elevated leverage and valuation gaps. The consensus recommendation remains a “buy,” but execution timing is critical. Maintaining a disciplined approach to entry levels near support (£2,000) could improve risk‑adjusted returns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technical bullish MACD vs longer‑term bearish SMA placement
- Recent earnings beat but share price dip on growth concerns
- High valuation relative to DCF and elevated volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst median target indicating ~24% upside
- Sustained 7% organic revenue growth and high client retention
- Attractive dividend yield supporting total return
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Diversified global service portfolio reduces cyclical exposure
- Strong cash‑flow generation despite leverage
- Long‑term secular demand for outsourced food and facilities services
Key Metrics & Analysis
Financial Health
Revenue Growth10.60%
Profit Margin4.05%
P/E Ratio27.8
ROE25.64%
ROA7.42%
Debt/Equity90.71
P/B Ratio673.4
Op. Cash Flow£3.4B
Free Cash Flow£1.6B
Technical Analysis
TrendBearish
RSI58.0
Support£2,000.00
Resistance£2,326.00
MA 20£2,184.10
MA 50£2,231.42
MA 200£2,447.13
MACDBullish
VolumeStable
Fear & Greed Index75.89
Valuation
Fair Value£1,719.80
Target Price£2,834.49
Upside/Downside24.16%
GradeOvervalued
TypeBlend
Dividend Yield2.12%
Risk Assessment
Beta0.17
Volatility30.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.